Download PDF
Thromb Haemost 2002; 88(02): 213-220
DOI: 10.1055/s-0037-1613190
In Focus
Schattauer GmbH

Chemotherapy-Induced Activation of Hemostasis: Effect of a Low Molecular Weight Heparin (Dalteparin Sodium) on Plasma Markers of Hemostatic Activation

Ilene C. Weitz
1   Divisions of Hematology, Kenneth Norris Jr Comprehensive Cancer Center
2   California Cancer Medical Center, University of Southern California-Keck School of Medicine, Los Angeles, CA, USA
,
Valerie K. Israel
3   Medical Oncology, Department of Medicine, Kenneth Norris Jr Comprehensive Cancer Center
,
James R. Waisman
3   Medical Oncology, Department of Medicine, Kenneth Norris Jr Comprehensive Cancer Center
,
Cary A. Presant
2   California Cancer Medical Center, University of Southern California-Keck School of Medicine, Los Angeles, CA, USA
3   Medical Oncology, Department of Medicine, Kenneth Norris Jr Comprehensive Cancer Center
,
Leanne Rochanda
1   Divisions of Hematology, Kenneth Norris Jr Comprehensive Cancer Center
,
Howard A. Liebman
1   Divisions of Hematology, Kenneth Norris Jr Comprehensive Cancer Center
› Author Affiliations
Further Information

Publication History

Received 15 January 2002

Accepted 18 April 2002

Publication Date:
07 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Purpose

To evaluate the effect of standard chemotherapeutic regimens on the hemostatic profile of patients with breast and lung carcinoma; and to evaluate the effect of a single dose of a low molecular weight (LMW) heparin, dalteparin sodium, administered prior to the chemotherapy on markers of hemostatic activation.

Patients and Methods

11 patients with breast cancer and 10 patients with lung cancer receiving systemic chemotherapy were studied. 10 breast cancer patients and 9 lung cancer patients completed at least 1 cycle of treatment and had all hemostatic studies. Patients had a complete hemostatic and prothrombotic profile performed at study initiation. Markers of hemostatic activation consisting of immunoassays for thrombin-antithrombin (TAT) complex and D-dimer were measured in plasma samples obtained prior to chemotherapy and at 1, 24 and 48 h after treatment. A 2500 U dose of dalteparin was given prior to the 2nd cycle of chemotherapy; 5000 U of dalteparin was given prior to the 4th treatment cycle.

Results

Chemotherapy resulted in statistically significant increases in TAT and D-dimer for the 1, 24 and 48 h plasma samples in both the breast and lung cancer patients for all cycles of chemotherapy given without LMW heparin. There were statistically significant increases in basal thrombin generation over the 4 cycles of treatment which was unrelated to active cancer. Both pretreatment doses of dalteparin effectively prevented increases in the markers of hemostatic activation. However, in the lung cancer patients, who had significantly increased basal thrombin generation, the 5000 U dose dalteparin was more effective.

Conclusion

Chemotherapy results in significant hemostatic activation in patients with breast and lung cancer. The effect of treatment appears to be cumulative. A single dose of LMW heparin administered prior to therapy can suppress hemostatic activation.

This project was funded by a grant from the Pharmacia corporation

Keywords

Cancer - chemotherapy - hemostatic activation - thrombosis
 

  • References

  • 1 Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale de l’Hotel- Dieu de Paris. Paris: JB Balliere et Fils; 1865. 3: 654-712.
    Search in Google Scholar
  • 2 Sack GH, Levin J, Bell W. Trousseau’s Syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasm: clinical, pathophysiologic and therapeutic features. Medicine (Baltimore) 1977; 56: 1-37.
    CrossrefPubMedSearch in Google Scholar
  • 3 Rickles FR, Levine MN, Dvorak HF. Abnormalities of Hemostasis in Malignancy in Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th Edition. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Philadelphia: Lippincott Williams & Wilkins; 2000: 1131-52.
    Search in Google Scholar
  • 4 Lyman GH, Bettigole RE, Robson E, Ambrus JL. Fibrinogen kinetics in patients with neoplastic disease. Cancer 1978; 41: 1113-22.
    CrossrefPubMedSearch in Google Scholar
  • 5 Yoda Y, Abe T. Fibrinopeptide A (FPA) levels and fibrinogen kinetics in patients with malignant disease. Thromb Haemost 1981; 46: 706-9.
    Thieme ConnectPubMedSearch in Google Scholar
  • 6 Edwards RI, Rickles FR, Cronlund M. Abnormalities in blood coagulation with cancer. Mononuclear tissue factor generation. J Lab Clin Med 1981; 98: 917-28.
    PubMedSearch in Google Scholar
  • 7 Bertomeu MC, Gallo S, Lauri D, Levine MN, Orr FW, Buchanan MR. Chemotherapy enhances endothelial cell reactivity to platelets. Clin Expl Metastasis 1990; 08: 511-8.
    CrossrefPubMedSearch in Google Scholar
  • 8 Rickles FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11: 237-48.
    CrossrefPubMedSearch in Google Scholar
  • 9 Clarke-Pearson DL, Creasman WT, Coleman RE, Synan IS, Hinshaw WM. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized trial. Gynecol Oncol 1984; 18: 222-32.
    PubMedSearch in Google Scholar
  • 10 Clagett GP, Reisch JS. Prevention of venous thormboembolism in general surgical patients. Ann Surg 1988; 208: 227-40.
    CrossrefPubMedSearch in Google Scholar
  • 11 Raaf J. Results from the use of 826 vascular access devices in cancer patients. Cancer 1985; 55: 1312-21.
    CrossrefPubMedSearch in Google Scholar
  • 12 Weitz IC, Israel VK, Liebman HA. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden. Cancer 1997; 79: 2024-7.
    CrossrefPubMedSearch in Google Scholar
  • 13 Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 1981; 63: 677-9.
    PubMedSearch in Google Scholar
  • 14 Levine MN, Gent M, Hirsch J, Arnold A, Goodyear MD, Hryniuk W, DePauw S. The thrombogeneic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-7.
    CrossrefPubMedSearch in Google Scholar
  • 15 Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 09: 286-94.
    CrossrefPubMedSearch in Google Scholar
  • 16 Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984; 54: 1264-8.
    CrossrefPubMedSearch in Google Scholar
  • 17 Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR. Heparin abolishes the chemotherapy-induced increase in plasma Fibrinopeptide A Levels. Am J Med 1990; 89: 25-8.
    CrossrefPubMedSearch in Google Scholar
  • 18 Levine M, Hirsch J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard KI, Stewart D, Goodwin P. Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-9.
    CrossrefPubMedSearch in Google Scholar
  • 19 Weitz JI. Low molecular weight heparins. N Engl J Med 1997; 337: 668-98.
    PubMedSearch in Google Scholar
  • 20 Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK, Maher KT, Sanderson RM, Ward VP, Kakkar S. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-65.
    CrossrefPubMedSearch in Google Scholar
  • 21 Rickles FR, Edwards RL, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer 1983; 51: 301-7.
    PubMedSearch in Google Scholar
  • 22 Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983; 62: 14-31.
    PubMedSearch in Google Scholar
  • 23 Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Consonni R, Caccia R, Longatti S, Maran D, Rodeghiero F, Pogliani E, Marassi A, D’Angelo A, Barbui T. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993; 85: 745-50.
    CrossrefPubMedSearch in Google Scholar
  • 24 Nevasaari K, Heikkinen M, Taskinen PJ. Tamoxifen and thrombosis. Lancet 1978; 02: 946-7.
    PubMedSearch in Google Scholar
  • 25 Lipton A, Harvey H, Hamilton RW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 1984; 68: 887-9.
    PubMedSearch in Google Scholar
  • 26 Blackard CE, Byar DP, Jordan WP. Orchiectomy for advanced prostate carcinoma. Urology 1973; 01: 553-61.
    CrossrefPubMedSearch in Google Scholar
  • 27 Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 1986; 04: 1405-17.
    CrossrefPubMedSearch in Google Scholar
  • 28 Falanga A, Levine MN, Consonni R, Gritti G, Delaini F, Oldani E, Julian JA, Barbui T. The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial. Thromb Haemost 1998; 79: 23-7.
    Thieme ConnectPubMedSearch in Google Scholar